Adverse effects related to which aspect of health are not well documented during the drug approval process and are usually reported in case reports?

• A. Oral health
• B. Cardiovascular health
• C. Neurological health
• D. Dermatologic health

Answer: (A)

In drug safety, trials are designed to detect adverse effects on major organ systems and rely on systematic safety monitoring. Some areas aren’t closely tracked in approval studies, especially those that aren’t routinely assessed or are subjective and rare. Oral health fits this gap well: dental status and many oral side effects aren’t typically evaluated in standard trial safety protocols, and long-term or uncommon oral toxicities may not emerge in the controlled trial setting. When clinicians later encounter these unusual or idiosyncratic effects, they’re often described in case reports after a drug is on the market. In contrast, cardiovascular, neurological, and dermatologic effects are more routinely monitored during trials and postmarketing surveillance, so they’re less likely to be primarily revealed through case reports. So, adverse effects relating to oral health are the ones not well documented during the drug approval process and usually reported in case reports.